← All Onconetix, INC filings

Onconetix, INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
ONCO
Onconetix, INC
SCHEDULE: Altos Venture AG Boosts Onconetix Stake to 35.8% Following Make-Whole Share Issuance
Altos Venture AG significantly increased its beneficial ownership in Onconetix, Inc. to 35.8% of outstanding common stock after receiving 241,514 additional shares under a 'make-whole' provision.
NASDAQ
ONCO
Onconetix, INC
SCHEDULE 13D/A: Onconetix Officer Christian Bruhlmann Amends Ownership Disclosure, Reports 4.20% Stake After RSU Grant and Lock-Up Expiry
Christian Bruhlmann, Chief Strategy Officer of Onconetix, Inc., filed an amended Schedule 13D to update his beneficial ownership to 4.20% of common stock, reflecting a recent RSU grant and the expiration of a lock-up agreement.
NASDAQ
ONCO
Onconetix, INC
SCHEDULE 13D/A: Onconetix Interim CEO Ralph Schiess Updates Stake Following RSU Grant and Proteomedix Acquisition Integration
Onconetix, Inc. has filed an amended Schedule 13D revealing that Interim CEO and Chief Science Officer Ralph Schiess's beneficial ownership now stands at 4.63% after receiving a grant of restricted stock units and the conversion of preferred stock related to the Proteomedix acquisition.